Stock MICROBOT MEDICAL INC
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News Microbot Medical Inc Nasdaq

Equities

US59503A1051

Biotechnology & Medical Research

Search
See the results
Microbot Medical® Strengthens Its Commercial Capabilities with the Addition of David J. Wilson to the Board of Directors
Jan. 13
 GL
Microbot Medical Completes $8.6 Million Registered Direct Offering
Jan. 10
 MT
Microbot Medical Closes $8.6 Million Registered Direct Offering
Jan. 10
 GL
Microbot Medical Announces $8.6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
Jan. 08
 GL
Microbot Medical Announces $8.6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
Jan. 08
 AQ
Microbot Medical Raises a Total of Approximately $11.8 Million in Gross Proceeds from Registered Direct Offering and Previously Announced ATM Facility
Jan. 07
 GL
Microbot Medical Raises a Total of Approximately $11.8 Million in Gross Proceeds from Registered Direct Offering and Previously Announced ATM Facility
Jan. 07
 AQ
Microbot Medical Announces $7 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
Jan. 06
 GL
Microbot Medical Announces $7 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
Jan. 06
 AQ
Top Premarket Gainers
Jan. 06
 MT
Microbot Medical® Concludes 2024 by Achieving Key Milestones Culminating in FDA Submission for the Commercialization of LIBERTY®
Dec. 30
 GL
Microbot Medical : reg; Concludes 2024 by Achieving Key Milestones Culminating in FDA Submission for the Commercialization of LIBERTY® Form 8 K
Dec. 30
 PU
Microbot Medical Inc. Concludes 2024 by Achieving Key Milestones Culminating in FDA Submission for the Commercialization of LIBERTY
Dec. 30
 CI
Microbot Medical Inc. Appoints David J. Wilson as Class III Director
Dec. 19
 CI
Microbot Medical® CEO Harel Gadot to Discuss Endovascular Robotics on Benzinga All Access
Dec. 10
 GL
Microbot Medical : reg; Announces FDA Submission for the Commercialization of the LIBERTY® Endovascular Robotic System Form 8 K
Dec. 10
 PU
Microbot Medical® Announces FDA Submission for the Commercialization of the LIBERTY® Endovascular Robotic System
Dec. 10
 GL
Microbot Medical Inc. Announces FDA Submission for the Commercialization of the LIBERTY Endovascular Robotic System
Dec. 10
 CI
Microbot Medical Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024
Nov. 13
 CI
Microbot Medical : Announces the Successful Completion of its Pivotal Human Clinical Trial; Accelerates Go to Market Strategy to Prepare for Commercial Launch of LIBERTY® during 2Q 2025 Form 8 K
24-10-15
 PU
Microbot Medical Announces the Successful Completion of its Pivotal Human Clinical Trial; Accelerates Go-to-Market Strategy to Prepare for Commercial Launch of LIBERTY® during 2Q 2025
24-10-15
 GL
Microbot Medical Announces the Successful Completion of its Pivotal Human Clinical Trial; Accelerates Go-to-Market Strategy to Prepare for Commercial Launch of LIBERTY® during 2Q 2025
24-10-15
 AQ
Microbot Medical Inc. Announces Successful Completion of Its Pivotal Human Clinical Trial
24-10-15
 CI
Microbot Medical : Proxy Statement Form 8 K
24-10-11
 PU
Microbot Medical Says it Expects to Finish its ACCESS-PVI Robotic Surgical System Clinical Trial Ahead of Schedule
24-09-30
 MT
Become a member to access more news.
100% Free Registration
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MBOT Stock
  4. Stock
  5. News Microbot Medical Inc